Extracorporeal liver cross-circulation using transgenic xenogeneic pig livers with brain-dead human decedents
Abraham Shaked / nature - Nature Medicine, Published online: 09 February 2026; doi:10.1038/s41591-025-04196-3In a study of four brain-dead human decedents, extracorporeal liver cross-circulation using genetically modified pig livers provides essential hepatic functions, supporting…
AI Summary: In a controversial translational study investigators ran blood between genetically modified pig livers and brain‑dead human decedents using an extracorporeal cross‑circulation system to assess organ viability and function. The work explores a potential bridge to expand transplantable organs, laying technical groundwork while prompting ethical and regulatory questions about next steps.
New FDA-Approved Device Uses Electric Fields to Treat Pancreatic Cancer
discovermagazine - Learn more about the newly approved wearable treatment that disrupts pancreatic cancer tumor growth while letting patients continue daily life at home.
AI Summary: The FDA approved a wearable device that delivers alternating electric fields to disrupt pancreatic tumor growth, letting patients remain ambulatory while receiving treatment. Clinicians hail the noninvasive approach as a new adjunct to standard care, aiming to slow progression in a cancer that’s notoriously hard to treat — and yes, it literally plugs into hope.
HPV cancer vaccine slows tumor growth and extends survival in preclinical model
medicalxpress - Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure. After proving this concept across multiple studies, the…
AI Summary: A therapeutic HPV vaccine showed tumor shrinkage and longer survival in preclinical models of HPV‑driven oropharyngeal cancer, suggesting a possible adjunct to surgery and chemo‑radiation. Researchers say the approach could boost anti‑tumor immunity and inform next‑stage trials, though human efficacy and safety await clinical proof.
Cigna to lay off 2,000 workers worldwide
Rebecca Pifer Parduhn / healthcaredive - Cigna’s layoffs follow other recent downsizing announcements from health insurers looking to cut costs during an era of heightened medical spending.
AI Summary: Health insurer Cigna announced a workforce reduction of roughly 2,000 positions worldwide as part of a cost‑cutting and restructuring push. Executives framed the layoffs as necessary to right-size operations amid rising medical spending and business pressures, leaving affected employees to navigate the inevitable chaos of corporate belt‑tightening.
FDA clears 1st blood test for Alzheimer’s in primary care
Ella Jeffries / beckershospitalreview - The first FDA-cleared blood test to assess Alzheimer’s disease in primary care is now available for patients age 55 and older with symptoms of cognitive decline. The test aims to help clinicians rule out Alzheimer’s by identifying individuals unlikely to …
AI Summary: Regulators cleared the first blood test for Alzheimer’s for primary‑care use while researchers published capillary sampling methods and analyses showing blood biomarkers’ promise for dementia diagnosis. Together these developments push biomarker testing out of specialty clinics and toward routine care — promising earlier detection, though concerns about population diversity, accuracy thresholds and rollout logistics remain.
Studies test whether gene-editing can fix high cholesterol. For now, take your medicine
medicalxpress - Scientists are testing an entirely new way to fight heart disease: a gene-editing treatment that might offer a one-time fix for high cholesterol.
AI Summary: Researchers are testing gene‑editing approaches aimed at providing a single‑procedure solution for elevated LDL cholesterol. Early human studies probe safety and durability, but experts urge patients to continue proven lipid‑lowering therapies for now. The line between ambitious science and everyday clinical care remains prudently guarded.
Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B
Frank Vinluan / medcitynews - Orna Therapeutics brings Eli Lilly an in vivo cell therapy ready for Phase 1 testing as a potential treatment for autoimmune diseases. Lilly is now the latest pharma company to use M&A to enter this growing field, following deals made in the past year by …
AI Summary: Eli Lilly is acquiring Orna Therapeutics for up to $2.4 billion to secure in‑vivo cell‑therapy capabilities and jump‑start its presence in CAR‑T and immune‑resetting platforms. The deal signals big pharma’s move to couple traditional drug development muscle with next‑generation cell‑engineering, accelerating clinical testing and commercialization plans.
Sanofi's Paul Hudson out, with Belén Garijo to step in as new CEO
Reynald Castañeda / endpoints - Paul Hudson is stepping down from his post as CEO of Sanofi, and his last day will be Feb. 17. The French drugmaker's board decided not to renew Hudson's mandate on ...
AI Summary: Sanofi’s board has opted not to renew Paul Hudson’s tenure, installing Belén Garijo as the new chief executive amid mixed reactions. The leadership swap arrives as the French drugmaker faces pipeline pressures and investor impatience—expect strategic shuffles, belt‑tightening and plenty of corporate soul‑searching with a side of investor scrutiny.
FDA to reassess the safety of BHA, a preservative used in popular snack foods
go - Federal health officials will reassess the safety of a chemical called BHA used in foods including potato chips, cereals, frozen meals and meat products
AI Summary: U.S. regulators have moved to reevaluate butylated hydroxyanisole (BHA), a common food preservative, ordering a fresh safety review after mounting evidence and public concern. The reassessment could lead to updated guidance or restrictions — which will delight activists and mildly inconvenience snack manufacturers.
Report reveals a significant global palliative care gap among children
medicalxpress - Nearly all the world's 10.6 million children experiencing serious health-related suffering (SHS) live in low- and middle-income countries with little to no access to palliative care or specialized care for their illness, according to a comprehensive new r…
AI Summary: A new global analysis reveals roughly 10.6 million children live with serious health‑related suffering and face a striking lack of pediatric palliative services, especially in low‑ and middle‑income countries. The study calls for urgent policy, training and resource commitments to close the gap and reduce needless pain for sick children — because saying “we’ll do better” is no longer enough.
Ama launches independent vaccine review after CDC criticism
medicalxpress - Two major medical groups will begin reviewing vaccine safety and effectiveness after major changes at the U.S. Centers for Disease Control and Prevention (CDC) have raised alarms among experts.
AI Summary: The American Medical Association announced an independent review of vaccine safety and effectiveness in response to recent CDC changes and criticism, partnering with external researchers to evaluate evidence and restore public trust. The panel aims to provide transparent, expert analysis free of political noise.
Solace Health Reaches Unicorn Status by Taking the ‘Homework’ Out of Care Navigation
Katie Adams / medcitynews - Health advocate network Solace Health gained unicorn status after closing a $130 million Series C funding round. The startup’s advocates help with tasks like scheduling appointments, finding in-network providers, understanding insurance coverage and bills…
AI Summary: Care navigation startup Solace Health closed a $130 million Series C, achieving a $1 billion valuation by expanding its patient advocacy network that helps members navigate benefits and care. The funding will scale operations and deepen employer and payer partnerships aimed at reducing administrative friction.
BridgeBio Stands Tall as Phase 3 Data Put Dwarfism Drug on Track for FDA Filing
Frank Vinluan / medcitynews - Infigratinib achieved statistically significant improvement in growth rate and body composition in a Phase 3 clinical trial that tested the BridgeBio Pharma drug in achondroplasia, the most common form of dwarfism. Regulatory submissions are planned for l…
AI Summary: BridgeBio reported statistically significant Phase 3 results for infigratinib in achondroplasia, showing improved growth rates and body composition, moving the program toward an FDA filing. The readout strengthens BridgeBio’s rare-disease momentum and sets the stage for regulatory discussions and potential market entry.
Talkiatry Rakes In $210M to Scale Virtual Psychiatry Group
Katie Adams / medcitynews - Telepsychiatry provider Talkiatry has raised a $210 million Series D round led by Perceptive Advisors, bringing its total funding to more than $400 million. CEO Robert Krayn said the company is focused on scaling its clinician-employed model and improving…
AI Summary: Talkiatry closed a $210 million Series D led by Perceptive Advisors to scale its virtual psychiatry platform, expanding telepsychiatry access and accelerating growth plans. The financing positions the company to beef up operations, hire talent, and deepen partnerships as demand for remote mental health care surges.
AbbVie sues over selection of Botox for IRA negotiations
Nicole DeFeudis / endpoints - AbbVie is suing CMS for picking Botox for the third round of Medicare negotiations, making it the first drugmaker to challenge the upcoming cycle in court. In a lawsuit filed Wednesday in Washington, DC, AbbVie ...
AI Summary: AbbVie has filed suit challenging the federal decision to include Botox in Medicare’s drug price negotiation program, arguing the selection process was flawed and that the move could imperil innovation and pricing strategies. The lawsuit seeks to block or alter implementation while the industry and regulators brace for legal precedent.
Kaiser Permanente, DoL reach settlement over mental health access
fiercehealthcare - Kaiser Foundation Health Plan has agreed to a settlement with the Department of Labor that resolves multiple investigations into access for mental health and substance abuse services.
AI Summary: Kaiser Foundation Health Plan reached a settlement with the U.S. Department of Labor resolving investigations into alleged failures to provide adequate mental‑health access. The move comes amid rolling labor actions at Kaiser — pharmacy and lab employees briefly struck and later stood down while nurse‑led walkouts continued — exposing labor tensions and regulatory pressure.
Thousands of NYC nurses return to work, but one major strike goes on
medicalxpress - A monthlong nurses strike in New York City is coming to an end, but not for everyone.
AI Summary: After weeks of labor turmoil, most striking New York City nurses have tentatively returned under new agreements, but a substantial contingent at a major hospital remains on strike. Patients and families report care disruptions and uncertainty as remaining negotiations continue, highlighting strain on hospitals and lingering tensions between staff and management.
500M records exchanged through TEFCA, federal health IT office boasts
fiercehealthcare - At the 2026 Annual Meeting for the health IT office at HHS, officials announced a massive spike in the number of health records shared through the government-backed TEFCA initiative. The number seems to reflect the heavy focus Trump's HHS has put on digit…
AI Summary: The federal Trusted Exchange Framework and Common Agreement (TEFCA) has passed roughly 500 million health records exchanged across participating networks, a milestone officials say will accelerate interoperability and data flow. The milestone spotlights rapid uptake and complementary data initiatives—plus the governance and privacy work that now comes with scale.
Federal judge blocks $602M in CDC cuts to 4 states
Kelly Gooch / beckershospitalreview - A federal judge in the Northern District of Illinois granted a temporary restraining order Feb. 12 blocking the Trump administration from terminating more than $600 million in CDC-administered public health grants to California, Colorado, Illinois and Min…
AI Summary: A federal judge issued a temporary restraining order halting the administration’s planned termination of roughly $600M in CDC grants to several states, siding with lawsuits that argued the cuts would impair public-health programs. The order preserves funding while courts consider claims that the move would cause immediate harm.
Microfluidic automation improves oocyte recovery from follicular fluid of patients undergoing in vitro fertilization
Baris R. Mutlu / nature - Nature Medicine, Published online: 12 February 2026; doi:10.1038/s41591-026-04207-xThe authors developed a microfluidic device, FIND-Chip, designed to automate and enhance oocyte recovery from follicular fluid, a process traditionally done manually. When …
AI Summary: Researchers developed a microfluidic automation device that finds and recovers viable oocytes missed by standard follicular‑fluid inspection, increasing oocyte yield for IVF. The approach — validated in lab and early clinical settings — promises to improve embryo selection and fertility outcomes by reducing human oversight errors in the lab.